Navigation Links
Debiopharm and EPFL Establish an Oncology Chair
Date:2/27/2008

LAUSANNE, Switzerland, February 27 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, today announced the establishment of a Debiopharm oncology chair at the Ecole Polytechnique Federale de Lausanne (EPFL), focusing on Signal Transduction in Oncogenesis. Funded through a CHF 2.5 million endowment, the objective of the chair is to leverage the wide scope of ideas and inventions discovered by EPFL scientists and the global drug development expertise of Debiopharm. The synergy expected through this partnership will maximise the chances of bringing innovative drugs to patients.

The Debiopharm oncology chair will support the research work of Assistant Professor Dr Joerg Huelsken, of the EPFL Faculty of Life Sciences, which focuses on the role of the WNT signalling pathway in tumorigenesis and stem cell maintenance. Under the terms of the agreement, Debiopharm will also finance other potential collaborative research projects of mutual interest to both parties and will have the option to endow a second chair in Drug Design.

"The creation of this oncology chair will reinforce our involvement in local research," said Kamel Besseghir, CEO of Debiopharm S.A. "We are in close vicinity to the EPFL and have been collaborating on various projects over the past years. Our recently established office at the EPFL will contribute to build a critical mass in biomedical research in the Lake Geneva region, help us identify new projects and blend our ideas."

"The timing of our oncology chair at the EPFL could not have been better. The move of ISREC (Swiss Institute for Experimental Cancer Research) to the EPFL this year will increase their concentration of oncology expertise," added Rolland-Yves Mauvernay, President and Founder of Debiopharm Group."

"This partnership with Debiopharm is an example of how academic research and pharmac
'/>"/>

SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
2. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
3. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care
6. European Centre for Modern Drug Discovery Established in Hamburg
7. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. KGI and Smith College Establish Leadership Forum for Women in Bioscience
10. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
11. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas City ... firms and animal health companies to hear from animal health companies with the ... also received licensing agreements or distribution contracts. This meeting is one of ...
(Date:8/27/2015)... , Aug. 27, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that executives from ... the month of September.  , ... Rodman & Renshaw,s 17th Annual Global Investment Conference on ... the St. Regis Hotel in New York ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's ... narrows down the product choices to a manageable shortlist of bench and floor ... to models that fit best with the customer’s industry and application. , ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2METTLER TOLEDO Updates Online Scale Selection Tool 2
... NEWARK, N.J., Aug. 5 BioNeutral Group, Inc. ("BioNeutral") (OTC ... Company announced today independent steel corrosion test results conducted at ... Grade Antimicrobial was found to be completely non-corrosive to steel. ... available antimicrobials and cleaners are corrosive to iron and steel. ...
... , SAN DIEGO, Aug. 5 Ceregene, Inc. today ... for long-term follow-up testing of patients enrolled in the company,s Phase ... enable Ceregene to collect and analyze more extensive data for up ... enrolled in the double-blind, controlled trial which ended in November 2008. ...
... , , , ... ) today reported financial results for the second quarter ended June 30, ... 2009 of $12.4 million, or $0.37 per share, which was in line ... second quarter of 2008 of $8.1 million, or $0.29 per share. ...
Cached Biology Technology:BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing 2BioNeutral's Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing 3Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients 2Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients 3Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients 4Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 2Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 3Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 4Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 5Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results 6
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
(Date:8/19/2015)... Aug. 19, 2015  VOXX International Corporation (Nasdaq: ... entered into a Definitive Agreement to purchase the ... authentication market leader EyeLock through an acquiring entity.  ... a controlling interest in the acquiring entity. The ... of due diligence.  Expanding on its existing supply ...
(Date:8/17/2015)... , Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... new sales campaign for Q4 2015. The new marketing ... team consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) ... Group is a leader in retail driven marketing and ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... blocks for next-generation computer memory has earned a University ... award. Vassiliy Lubchenko, an assistant professor of ... Alfred P. Sloan Research Fellow for his achievements and ... 54 colleges and universities in the United States and ...
... laboratory research using magnetically guided nanoparticles to deliver drugs ... has just spun off its first startup company, Vascular ... VMI, a new company formed to develop the lab ... to create a novel, greatly needed treatment for peripheral ...
... Obesity appears to impair normal muscle function ... implications for humans, according to Penn State researchers. ... accumulating excess fat and carrying excess weight," said ... in physiological genomics, Penn State College of Medicine. ...
Cached Biology News:UH chemist investigates material for next-generation computer memory 2CHOP partners with Vascular Magnetics, Inc. to pursue commercial potential of blood vessel research 2CHOP partners with Vascular Magnetics, Inc. to pursue commercial potential of blood vessel research 3Obesity creates wimpy rats 2
Normal serum collected from healthy Kunming mice....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
... Services include: ,ISH Protocol Development ... Analyses ,RNA and DNA Screenings ... and Tissues ,Double Labeling of ... and Tissues ,RNA and DNA ...
Request Info...
Biology Products: